{"schema_version":"secwatch.filing_event.v1","accession":"0001551306-24-000018","form_type":"8-K","ticker":"PGNY","cik":"0001551306","company_name":"Progyny, Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.575605+00:00","generated_at":"2026-06-05T11:46:26.663136+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Progyny reports record FY23 revenue $1.09B (+38%); guides FY24 $1.285-$1.315B","bullets":["FY23 revenue $1,088.6M (+38% YoY); net income $62.0M ($0.62 diluted EPS), adj. EBITDA $187.1M (+49%).","Q4 revenue $269.9M (+26%); net income $13.5M ($0.13 EPS); adj. EBITDA $43.2M (+31%).","Clients grew to 392 as of Dec 31, 2023, from 288 a year earlier; expects >460 clients in 2024.","FY24 revenue guidance $1.285-$1.315B (+18-21%), adj. EBITDA $224-$232M, adj. EPS $1.54-$1.59.","Q1 2024 revenue guided $285-$292M (+10-13%); cites ~$15M headwind from short-term treatment mix shift."],"urls":{"canonical":"https://secwatch.observer/filing/0001551306-24-000018","json":"https://secwatch.observer/filing/0001551306-24-000018.json","markdown":"https://secwatch.observer/filing/0001551306-24-000018.md","text":"https://secwatch.observer/filing/0001551306-24-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551306/000155130624000018/0001551306-24-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551306/000155130624000018/pgny-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T11:46:26.663136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b616042174c6c8a769e625cbf2d8e0f0cf76560","claim":"Progyny, Inc. reported financial results for the fiscal quarter and year ended December 31, 2023.","evidence_excerpt":"On February 27, 2024, Progyny, Inc. (the \"Company\") issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551306/000155130624000018/0001551306-24-000018-index.htm","confidence":0.6,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"cb355a991aeaa4a9ab2e383a1628a63288108ede","claim":"Progyny, Inc. reported the three- and twelve-month periods ended December 31, 2023 results: revenue $1,088.6 Million, net income $62,037, EPS $0.62. Guidance initiated.","evidence_excerpt":"Progyny, Inc. Announces Fourth Quarter 2023 Results Reports Record Full Year Revenue of $1,088.6 Million, Reflecting 38% Growth Achieves 49% Growth in Adjusted EBITDA to Record $187.1 Million Issues Financial Guidance for 2024, Crossing the $1.3 Billion Milestone at Midpoint","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551306/000155130624000018/0001551306-24-000018-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three- and twelve-month periods ended December 31, 2023"},{"label":"Revenue","value":"$1,088.6 Million"},{"label":"Net income","value":"$62,037"},{"label":"EPS","value":"$0.62"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}